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Abstract 26 
Background: Faecal carriage of extended-spectrum beta- lactamase (ESBL) producing Enterobacteriaceae 27 
in healthy individuals was examined and compared to previous results obtained in such individuals a few 28 
years earlier. 29 
Methods: Faecal samples from 779 individuals screened for employment purposes and from 225 30 
applicants to long-term care (LTC) were screened between November 2013 and May 2014.  31 
Results: The overall rate of fecal carriage was 3.0% (30/1004). The carriage rate was significantly higher 32 
in applicants for LTC (5.3% vs. 2.3%; p=0.019). All isolates carried CTX-M ESBLs, with an 33 
overwhelming dominance of blaCTX-M-15 (84.4%) in both groups and in both E. coli and Klebsiella 34 
pneumoniae.  35 
Conclusions: The prevalences were comparable to those in the earlier study, but a marked decrease of the 36 
diversity of ESBL genes in E. coli from the employment screening group was found, suggesting that the 37 
ESBL-producing isolates originating from diverse sources are being replaced by highly successful blaCTX-38 
M-15 producing strains. 39 
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Introduction 41 
The gut flora of humans and animals is undoubtedly a significant reservoir of plasmids harbouring ESBL 42 
genes as well as of ESBL producers [1] and may serve as a source of endogeneous or exogeneous 43 
infections [2]. A change in the epidemiology of ESBL producing Enterobacteriaceae took place when 44 
CTX-M-type enzymes became prevalent first in the hospital and then in the community setting. Their 45 
high ability to disperse locally in the community [3] and to disperse long-range via international travel [4] 46 
has been reported. Asymptomatic carriers play an increasingly important role in the epidemiology of 47 
ESBL producers. It is, therefore, important to monitor changes in the prevalence, distribution and 48 
dynamics of ESBL producers not only in infected patients, but in asymptomatic carriers as well. The aim 49 
of the present study was to survey the faecal carriage rate of ESBL producers among healthy individuals 50 
and to compare with results obtained in the same population a few years earlier [5].  51 
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Material and methods 53 
Stool samples from 779 healthy individuals screened for employment purposes (599 females, 180 males; 54 
median age 34 (range 14-61) years) and from 225 applicants to long-term care (LTC) facilities (140 55 
females, 85 males; median age 81 (range 0-103) years) were analysed between November 2013 and May 56 
2014 and compared with results obtained in 2009-2010 in the same population. As the study involved 57 
only the samples sent for routine screening purposes and the patients were unidentified, informed consent 58 
could not be obtained and and approval by an Ethics Review Board was not required. 59 
To screen for ESBL production, faecal samples were inoculated onto eosin methylene blue agar plates 60 
supplemented with 2 mg/l cefotaxime. Confirmation of ESBL phenotype was performed using double 61 
disk synergy test (Oxoid, Basingstoke, UK). The isolates were identified by MALDI Biotyper (Bruker, 62 
Bremen, Germany) and by species-specific PCRs. Susceptibility to ertapenem, meropenem, imipenem, 63 
cefotaxime, ceftazidime, cefepime, ciprofloxacin, co-trimoxazole, colistin, amikacin, gentamicin and 64 
tobramycin was tested by disk diffusion according to EUCAST recommendations. All isolates were 65 
screened for the genes blaTEM, blaSHV, and blaCTX-M, amplified genes were sequenced. Five 66 
aminoglycoside resistance genes aac(3’)-IIa, aac(6’)-Ib, aph(3’)-Ia, ant(2”)-Ia, ant(3”)-Ia, and class 1 67 
and 2 integrons were sought for by PCRs. Gene cassette arrays were determined by sequencing. For 68 
Escherichia coli phylogenetic group and the clone O25b-ST131 were determined by PCRs. All technical 69 
protocols were described in our earlier publication [5]. Prevalences of isolates or genes were compared by 70 
chi-square or Fisher’s exact test as appropriate using PaSt 3.0. 71 
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Results and discussion 73 
The overall rate of fecal carriage of ESBL-producing isolates was 3.0% (30/1004). The carriage rate was 74 
significantly higher in applicants for LTC than in the employment screening group (5.3%, 12/225 vs. 75 
2.3%, 18/779; p=0.019). Thirty-two isolates produced ESBLs. Only E. coli isolates were found in the 76 
employment screening group, while in applicants for LTC five persons carried E. coli, another five 77 
carried K. pneumoniae, and further two carried both species simultaneously. 78 
All isolates carried CTX-M type ESBLs with an overwhelming dominance of blaCTX-M-15 (Table I). 79 
Diversity of ESBL genes was low. All K. pneumoniae isolates carried blaCTX-M-15 (two of them harboured 80 
blaSHV-5 and two other blaSHV-110 simultaneously), while six of seven E. coli isolates from the LTC group 81 
and 14 of 18 isolates from healthy individuals carried blaCTX-M-15. The remaining one and four E. coli 82 
isolates carried blaCTX-M-1. 83 
Resistance to other antibiotic classes than beta-lactamases was common.  Eleven, twelve, eight and 13 of 84 
14 isolates were resistant to ciprofloxacin, co-trimoxazole, gentamicin and amikacin, respectively, in the 85 
LTC group, while these numbers were eleven, eleven, six and six of 18 isolates in healthy individuals. 86 
This difference in susceptibility to amikacin was also evident when comparing only E. coli isolates. 87 
Integron carriage rates were comparable. In the LTC group class 1 integrons were detected in four K. 88 
pneumoniae (three and one with gene cassette arrays dfrA12-orfX-ant(3”)-Ib and dfrA15-ant(3”)-Ia, 89 
respectively) and three E. coli (one and two with gene cassette arrays dfrA7 and dfrA17-ant(3”)-Ie, 90 
respectively). Among E. coli isolates from healthy individuals six were class 1 integron carriers with one 91 
dfrA7, one dfrA1-ant(3”)-Ia, two ant(3”)-Ia and two dfrA17-ant(3”)-Ie gene cassette arrays. Class two 92 
integrons were found only in E. coli, one from the LTC and two from the employment screening group 93 
with a uniform gene cassette array of dfrA1-sat2-ant(3”)-Ia. The genes aac(3’)-IIa and aac(6’)-Ib were 94 
more frequently found in the LTC group than in healthy individuals (10/14 vs. 2/18, p=0.001 and 5/14 vs. 95 
0/18, p=0.02, respectively). This applied when comparing only E. coli isolates from the two groups (5/7 96 
vs. 2/18, p=0.007 and 3/7 vs. 0/18, p=0.015, respectively). Phylogroup distributions were comparable; 97 
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dominance of the pathogenic phylogroup B2 was found in the healthy individuals. All phylogroup B2 98 
isolates in both groups belonged to the blaCTX-M-15 producer O25b:ST131 pandemic clone.  99 
Compared with the 2009-2010 study [5], the over-all prevalence of ESBL producers was slightly lower. 100 
Though the prevalences of the two periods were statistically comparable, there was a significant 101 
difference between the overall gene distributions in the two periods as well as between gene distribution 102 
in the employment screening group. K. pneumoniae, found exclusively in the LTC group in both periods, 103 
became uniformly positive for blaCTX-M-15. Thus, production of SHV enzymes by K. pneumoniae became 104 
linked to simultaneous production of blaCTX-M-15. Remarkably, carbapenem (ertapenem) resistance, which 105 
appeared in K. pneumoniae isolated from inpatients in the same region [6], has not yet emerged. 106 
Similarly, in E. coli from the LTC group the gene blaCTX-M-15 became slightly more frequent (16/21 vs. 107 
6/7), and became predominant in healthy individuals as well, but this difference was not statistically 108 
significant. In the earlier study five of 22 isolates and in the present study 14 of 18 isolates carried blaCTX-109 
M-15 (Table I). This change was paralleled by increased resistance to ciprofloxacin and amikacin together 110 
with more frequent carriage of aac(3’)-IIa and aac(6’)-Ib, co-resistances and genes commonly associated 111 
with blaCTX-M-15 [7,8]. There was s significant difference in blaCTX-M-15 carriage between the LTC group and 112 
the employment screening group in the first period [5] but not in the second period. The similarity 113 
between the two groups in the present study suggests a scenario where the hospital based CTX-M-15 114 
producers have been established in the non-hospitalized group, i.e. in the community. 115 
Several studies report the emergence of blaCTX-M-15 producing E. coli in infections both in the hospital and 116 
in the community setting [9,10]. Assuming, as in the earlier study, that individuals in the LTC group are 117 
highly likely to have an extensive history of hospitalization in contrast to healthy individuals, the present 118 
study reports a direct observation of this emergence in asymptomatic carriers. This is underlined by the 119 
marked decrease of the diversity of ESBL genes in E. coli from the healthy individuals, where out of the 120 
six blaCTX-M enzymes representing all four major groups found in 2009-2010, only the blaCTX-M-15 and 121 
blaCTX-M-1 from group 1 remained in 2013-2014. This suggests that the ESBL-producing isolates 122 
originating from diverse sources [11-16], are being replaced by highly successful blaCTX-M-15 producing 123 
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strains. This epidemiological shift is confirmed by the replacement of commensal phylogroups by 124 
phylogroup B2 and is in parallel with the increase of the proportions of blaCTX-M-15 producers in both E. 125 
coli and K. pneumoniae isolated from inpatients from the same geographical area [6].   126 
Whether the community is the source or the target for these strains is debated. In some populations the 127 
importance of importation to the hospital has been shown [17-19], while previous hospitalization [20] as 128 
well as long-term care [5], are risk factors. In the geographical area of the study, exportation of blaCTX-M-15 129 
producing (phylogroup B2) E. coli isolates from the hospital to the community followed by spread within 130 
the community seems to take place, as suggested by the scenario outlined above. 131 
  132 
Page 7 of 12
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Acknowledgments 133 
The help of the technicians of the Synlab Ltd. during screening work is gratefully acknowledged. 134 
  135 
Page 8 of 12
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
References  136 
1. Woerther PL, Angebault C, Jacquier H, Hugede HC, Janssens AC, Sayadi S, et al. Massive increase, 137 
spread, and exchange of extended spectrum beta-lactamase-encoding genes among intestinal 138 
Enterobacteriaceae in hospitalized children with severe acute malnutrition in Niger. Clin Infect Dis 139 
2011;53:677-85.  140 
2. Damjanova I, Tóth A, Pászti J, Jakab M, Milch H, Bauernfeind A, et al. Epidemiology of SHV-type 141 
beta-lactamase-producing Klebsiella spp. from outbreaks in five geographically distant Hungarian 142 
neonatal intensive care units: widespread dissemination of epidemic R-plasmids. Int J Antimicrob Agents 143 
2007;29:665-71. 144 
 3. Valverde A, Grill F, Coque TM, Pintado V, Baquero F, Cantón R, et al. High rate of intestinal 145 
colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of 146 
infected community patients. J Clin Microbiol 2008;46:2796-9.  147 
4. Van der Bij AK, Pitout JD. The role of international travel in the worldwide spread of multiresistant 148 
Enterobacteriaceae. J Antimicrob Chemother 2012;67:2090-100. 149 
5. Ebrahimi F, Mózes J, Mészáros J, Juhász Á, Kardos G. Carriage rates and characteristics of 150 
Enterobacteriaceae producing extended-spectrum beta-lactamases in healthy individuals: comparison of 151 
applicants for long-term care and individuals screened for employment purposes. Chemotherapy 152 
2014;60:239-49.  153 
6. Ebrahimi F, Mózes J, Monostori J, Gorácz O, Fésűs A, Majoros L, et al. Comparison of the faecal 154 
colonization rates with extended-spectrum beta-lactamase producing enterobacteria among patients in 155 
different wards, outpatients and screened medical students. (submitted). 156 
7. Hansen DS, Schumacher H, Hansen F, Stegger M, Hertz FB, Schønning K, et al. Extended-spectrum 157 
beta-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: 158 
prevalence, beta-lactamase distribution, phylogroups, and co-resistance. Scand J Infect Dis 2012;44:174-159 
81. 160 
Page 9 of 12
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
8. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for 161 
Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with 162 
blaCTX-M genes. Clin Infect Dis 2004;38:1736-41. 163 
9. Hu F, O'Hara JA, Rivera JI, Doi Y. Molecular features of community-associated extended-spectrum-β-164 
lactamase-producing Escherichia coli strains in the United States. Antimicrob Agents 165 
Chemother 2014;58:6953-7.  166 
10. Smet A, Martel A, Persoons D, Dewulf J, Heyndrickx M, Claeys G, et al. Characterization of 167 
extended-spectrum beta-lactamases produced by Escherichia coli isolated from hospitalized and 168 
nonhospitalized patients: emergence of CTX-M-15-producing strains causing urinary tract infections. 169 
Microb Drug Resist 2010;16:129-34.  170 
11. De Boeck H, Miwanda B, Lunguya-Metila O, Muyembe-Tamfum JJ, Stobberingh E, Glupczynski Y, 171 
et al. ESBL-positive Enterobacteria isolates in drinking water. Emerg Infect Dis 2012;18:1019-20. 172 
12. Geser N, Stephan R, Hächler H. Occurrence and characteristics of extended-spectrum β-lactamase 173 
(ESBL) producing Enterobacteriaceae in food producing animals, minced meat and raw milk. BMC Vet 174 
Res 2012;8:21. 175 
13. Literak I, Dolejska M, Janoszowska D, Hrusakova J, Meissner W, Rzyska H, et al. 2010. Antibiotic-176 
resistant Escherichia coli bacteria, including strains with genes encoding the extended-spectrum beta-177 
lactamase and QnrS, in waterbirds on the Baltic Sea Coast of Poland. Appl Environ Microbiol 178 
2010;76:8126-34.  179 
14. Tacão M, Moura A, Correia A, Henriques I.  Co-resistance to different classes of antibiotics among 180 
ESBL-producers from aquatic systems. Water Res 2014;48:100-7. 181 
15. Tóth A, Juhász-Kaszanyitzky É, Mag T, Hajbel-Vékony G, Pászti J, Damjanova I. Characterization of 182 
extended-spectrum β-lactamase (ESBL) producing Escherichia coli strains isolated from animal and 183 
human clinical samples in Hungary in 2006-2007. Acta Microbiol Immunol Hung 2013;60:175-85. 184 
16. Wieler LH, Ewers C, Guenther S, Walther B, Lübke-Becker A. Methicillin-resistant staphylococci 185 
(MRS) and extended-spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae in companion 186 
Page 10 of 12
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
animals: nosocomial infections as one reason for the rising prevalence of these potential zoonotic 187 
pathogens in clinical samples. Int J Med Microbiol 2011;301:635-41. 188 
17. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Influx of 189 
extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect 190 
Dis 2006;42:925-34. 191 
18. Bert F, Larroque B, Paugam-Burtz C, Dondero F, Durand F, Marcon E, et al. Pretransplant fecal 192 
carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver 193 
transplant, France. Emerg Infect Dis 2012;18:908-16. 194 
19. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC, et al. Risk factors for 195 
colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit 196 
admission. Emerg Infect Dis 2007;13:1144-9. 197 
20. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, et al. Community-associated 198 
extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect 199 
Dis 2013;56:641-8. 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
 211 
 212 
Page 11 of 12
http://mc.manuscriptcentral.com/sinf  Email: infectious@informa.com
Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Table I. Comparison of the prevalence of ESBL and blaCTX-M-15 in the present study with an earlier study 213 
from the same population in the same region [5] 214 
 2009-10  
[reference 5] 
present study probability 
(P) 
Prevalence of ESBL in LTC 38/531(7.2%) 12/225 (5.3%) NS 
Prevalence of ESBL in employment 
screening group 22/1109 (2.0%) 18/779 (2.3%) NS 
Proportion of blaCTX-M-15 producers 
among ESBL producers 34/63 (54.0%) 27/32 (84.4%) 0.003 
Proportion of blaCTX-M-15 producing K. 
pneumoniae 11/18 7/7 NS 
Proportion of bla CTX-M-15 producing E. 
coli in LTC group 16/21 6/7 NS 
Proportion of bla CTX-M-15 producing E. 
coli in healthy individuals 5/22 14/18 ˂0.001 
 215 
LTC: Long-term care; NS: not significant 216 
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